Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma Services AG
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
To assess the progression-free survival (PFS) in patients who receive everolimus as second-line treatment for metastatic renal cell carcinoma
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen – an exploratory study of c-kit inhibition in allergic respiratory diseases
To assess the effects of Imatinib on allergic inflammation following repeated nasal allergen challenge (NAC) in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen – in particul...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo and oral corticosteroid in healthy volunteers
• To assess the ability of AIN457 to inhibit ozone-induced airway neutrophilia (total neutrophil cell count in 106/mL) in induced sputum at 24 hours compared to placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
To evaluate the bioavailability of: 5 x 1 mg everolimus intact tables, and 5 x 1 mg everolimus tablets suspended in 30 mL of water
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Phase II study for the treatment of abdominal aortic aneurysm
To assess the effect of ACZ885 on AAA size and growth rate as measured with ultrasound at 12 months.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy
Demonstrate the efficacy of the combination therapy of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis
Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal period
To evaluate a dose dependent reduction in MSSBP when comparing three doses of valsartan (0.25 mg,/kg, 1 mg/kg and 4 mg/kg ) over a 6 week period in children 1-5 years old with hypertension ( ≥ 95th p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, noninfectious, intermediate, posterior, or panuveitis requiring immunosuppression (INSURE Study)
To evaluate the efficacy of continuous treatment with subcutaneous AIN457 compared to placebo for maintaining quiescence of intraocular inflammation and the prevention of active intermediate, posterio...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Safety and efficacy of osilodrostat (LCI699) for the treatment of patients with Cushing's disease
To compare the complete response rate at the end of the 8-week period of randomized withdrawal (Week 34) between patients randomized to continued LCI699 therapy vs. placebo.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next